Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2015-08-03 | Anagenesis Biotechnologies (France) | Neuromuscular diseases - Regenerative medicine | |||
2015-08-03 | TXA127 | congenital muscular dystrophy (MDC1A) | preclinical | Tarix Orphan (USA - MA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
2015-07-31 | Actos® (pioglitazone) | type 2diabetes | post-marketing | Takeda Pharmaceutical (Japan) | Metabolic diseases |
2015-07-30 | avelumab (MSB0010718C) | solid tumors | 1 | Merck KGaA (Germany) | Cancer - Oncology |
2015-07-30 | MSB0011359C (M7824) | solid tumors | 1 | Merck KGaA (Germany) | Cancer - Oncology |
2015-07-29 | Keytruda® (pembrolizumab) and Halaven® (eribulin) | triple-negative breast cancer (TNBC) | 1-2 | Eisai (Japan) Merck&Co (USA - NJ) | Cancer - Oncology |
2015-07-29 | DNA-based monoclonal antibody (dMAb) targeting dengue virus | dengue fever | preclinical | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
2015-07-29 | volanesorsen (ISIS-APOCIIIRx) | patients with high to severely high triglycerides |
2 | Isis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Metabolic diseases |
2015-07-29 | APD334 - etrasimod | ulcerative colitis | 2b | Arena Pharmaceuticals (USA - CA) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2015-07-28 | epratuzumab | systemic lupus erythematosus | 3 | Immunomedics (USA - NJ) UCB (Belgium) | Autoimmune diseases - Inflammatory diseases |
2015-07-27 | INO-5150 | prostate cancer | 1 | Inovio Pharmaceuticals (USA - PA) | Cancer - Oncology |
2015-07-27 | tetravalent dengue vaccine candidate | dengue fever | 3 | Sanofi Pasteur (France) | Infectious diseases |
2015-07-27 | Bioabsorbable Cardiac Matrix BCM (BL-1040) | prevention of cardiac remodeling following an acute myocardial infarction (AMI) |
3 | BioLineRx (Israel) | Cardiovascular diseases |
2015-07-27 | IMA901 and sunitinib | metastatic renal cell carcinoma (RCC) | 3 | Immatics Biotechnologies (Germany) | Cancer - Oncology |
2015-07-27 | ALN-AAT | AAT deficiency-associated liver disease (alpha-1 liver disease) | 1-2 | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Liver diseases |
2015-07-24 | Prostvac® (rilimogene) | prostate cancer | 2 | Bavarian Nordic (Denmark) National Cancer Institute (NCI) (USA) | Cancer - Oncology |
2015-07-23 | anti-Abeta antibody MABT5102A (crenezumab) | prodromal-to-mild Alzheimer’s disease | 3 | Roche (Switzerland) AC Immune (Switzerland) | Neurodegenerative diseases |
2015-07-23 | AADVAC1 | Alzheimer\'s disease | 1 | Axon Neuroscience (Slovak Republic) | Neurodegenerative diseases |
2015-07-23 | masitinib | multiple sclerosis | 3 | AB Science (France) | Autoimmune diseases - Neurodegenerative diseases |
2015-07-22 | Vyvanse® (lisdexamfetamine dimesylate) | bing eating disorder |
3 | Shire (UK - USA) | CNS diseases - Mental diseases |